7-Chloroisoquinoline-1-carboxylic acid, 95.0%, 1g

benzyl 3-acetylazetidine-1-carboxylate, 95.0%, 10g

Z-4-chloro-DL-phenylalanine, 98.0%, 10g

2-(Difluoromethoxy)benzaldehyde>98.0%(GC)1g

Fmoc-D-Norleucine, 95.0%, 25g

Z-D-His-OH, 95+%, 250mg

N-METHOXY-N-METHYL-1-(TRIFLUOROMETHYL)CYCLOPROPANECARBOXAMIDE, 95.0%, 5g

Obiettivo IOS a fase piana PLPHi S100x/1.25 a immersione in olio corretto all'infinito. Distanza di lavoro 0,36 mm

ROTI®fenolo, 100 ml

(4S,4'S)-1,1'-Bis(3-(tert-butyl)phenyl)-4,4'-dicyclohexyl-4,4',5,5'-tetrahydro-1H,1'H-2,2'-biimidazole, 98%, 250mg

(4-(4-Methylthiazol-5-yl)phenyl)methanamine, 95.0%, 5g

tert-butyl 4-(aminomethyl)-3,3-difluoropyrrolidine-1-carboxylate, 97.0%, 500mg

(+/-)-Thalidomide, 98%, 250mg